Cocrystal Pharma, Inc.
Cocrystal Pharma is a clinical-stage biotechnology company that discovers and develops small-molecule antiviral drug candidates for serious or chronic viral diseases. It uses a proprietary structure-based drug discovery platform combining computational and medicinal chemistry, X-ray crystallography and other techniques to target viral replication enzymes and proteins. Its programs address influenza, coronaviruses, norovirus and hepatitis C. Cocrystal’s pipeline includes CC-42344, an influenza A candidate being developed for oral or inhaled use, and CDI-988, an oral candidate for norovirus and coronavirus infections. Its hepatitis C program includes CC-31244, and it also develops antivirals targeting influenza A and B. The company operates as one business entity and has not commercialized any product candidates, so it does not yet earn money from product sales. It works with contract research and manufacturing organizations and consultants on research and development. Cocrystal Pharma is headquartered in Bothell, Washington.
No SEC Form 4 filings for $COCP in the last 30 days.
See all $COCP insider activity →Cocrystal Pharma reported a Q3 2026 net loss of $3.4M, up from $2.0M a year ago, with $105K in revenue. The company completed Phase 1b dosing for its CDI-988 norovirus study, with preliminary efficacy results expected in late 2026.
H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.
Cocrystal Pharma (COCP) appointed Robert Sapirstein as CEO, with a compensation package tied to performance and equity. Phillip Frost, chairman of OPKO Health (OPK), invested $5 million in COCP. The company's board includes notable figures with pharmaceutical and corporate experience. COCP's antiviral candidate, CDI-988, is in Phase 1b trials with FDA Fast Track designation, targeting norovirus and other viruses. The company has $7.1 million in cash, providing a runway until Q1 2024.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning COCP (Cocrystal Pharma, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent COCP coverage spans corporate actions, financial news and earnings.
The increased loss and limited cash raise short‑term pressure on the stock, while upcoming efficacy data could be a catalyst.
Analyst upgrade with a new price target may drive buying interest.
New leadership and fresh capital could improve execution of the norovirus antiviral program.
Board appointment is a governance update with limited immediate fundamentals impact, but it can affect oversight and near-term sentiment.
The filing signals insider buying, but the disclosed size is modest and not tied to a 10b5-1 plan, limiting near-term fundamental impact.
AlphAI scores every news story that mentions COCP with an AI model for sentiment and relevance, and aggregates insider trades from Cocrystal Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cocrystal Pharma reported a Q3 2026 net loss of $3.4M, up from $2.0M a year ago, with $105K in revenue. The company completed Phase 1b dosing for its CDI-988 norovirus study, with preliminary efficacy results expected in late 2026.
H.C. Wainwright reiterated a Buy rating and $6.00 price target for Cocrystal Pharma (COCP), citing progress in its norovirus drug trial. The stock is up 15% premarket. COCP's Phase 1b study for CDI-988 is ongoing, with primary endpoints focused on efficacy against norovirus. Analysts have varying price targets, ranging from $8 to $10. COCP also announced a new board member, Carol L. Brosgart, effective August 12, 2026.
Cocrystal Pharma (COCP) appointed Robert Sapirstein as CEO, with a compensation package tied to performance and equity. Phillip Frost, chairman of OPKO Health (OPK), invested $5 million in COCP. The company's board includes notable figures with pharmaceutical and corporate experience. COCP's antiviral candidate, CDI-988, is in Phase 1b trials with FDA Fast Track designation, targeting norovirus and other viruses. The company has $7.1 million in cash, providing a runway until Q1 2024.
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 12, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed Carol L. B
FROST PHILLIP MD ET AL purchased 75,000 indirectly-held shares of Cocrystal Pharma, Inc. (COCP) at $0.94 on 2026-08-03.
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., August 3, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (N
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001412486 0001412486 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
Cocrystal Pharma, Inc. (COCP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001412486 0001412486 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants ...
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants
